Fondaparinux in Patients with Impaired Renal Function: The Right Choice?

  1. Keith A.A. Fox, MBChB
  1. From the University of Edinburgh, Edinburgh EH16 4SB, United Kingdom.

    IN RESPONSE:

    We thank Drs. Famularo and Minisola for their comments, but it is important to note that the dose of enoxaparin used in our study was the dose approved by regulatory agencies and recommended by acute coronary syndrome guidelines. To optimize both safety and efficacy, we chose the dose of fondaparinux on the basis of the …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med April 1, 2008 vol. 148 no. 7 561-562
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. December 1, 2009, 151 (11)
    1. Alert me to current issues